Exxonmobil Investment Management Inc. TX decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 13.6% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 141,290 shares of the medical research company’s stock after selling 22,251 shares during the quarter. Exxonmobil Investment Management Inc. TX’s holdings in Amgen were worth $24,334,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Camelot Portfolios LLC bought a new stake in shares of Amgen in the 1st quarter worth about $1,429,000. Shelton Capital Management grew its holdings in shares of Amgen by 82.7% in the 1st quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after purchasing an additional 49,354 shares during the last quarter. Telos Capital Management Inc. grew its holdings in shares of Amgen by 1.6% in the 1st quarter. Telos Capital Management Inc. now owns 14,348 shares of the medical research company’s stock worth $2,354,000 after purchasing an additional 227 shares during the last quarter. Cadence Bank NA grew its holdings in shares of Amgen by 6.2% in the 1st quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after purchasing an additional 197 shares during the last quarter. Finally, Palladium Partners LLC grew its holdings in shares of Amgen by 1.9% in the 1st quarter. Palladium Partners LLC now owns 112,042 shares of the medical research company’s stock worth $18,382,000 after purchasing an additional 2,079 shares during the last quarter. Institutional investors own 78.10% of the company’s stock.

Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.53% during mid-day trading on Friday, hitting $186.45. 3,017,323 shares of the company were exchanged. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $191.10. The company has a market capitalization of $136.05 billion, a price-to-earnings ratio of 16.98 and a beta of 1.35. The firm has a 50 day moving average of $175.99 and a 200 day moving average of $169.31.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the prior year, the business posted $2.84 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. Equities research analysts forecast that Amgen Inc. will post $12.57 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were issued a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.47%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s payout ratio is presently 41.93%.

AMGN has been the topic of several analyst reports. ValuEngine lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $203.00 target price (up previously from $189.00) on shares of Amgen in a report on Wednesday, July 26th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. BMO Capital Markets lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, July 26th. Finally, Mizuho reaffirmed a “buy” rating and issued a $198.00 target price (up previously from $183.00) on shares of Amgen in a report on Thursday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. Amgen presently has an average rating of “Buy” and a consensus price target of $188.41.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/exxonmobil-investment-management-inc-tx-sells-22251-shares-of-amgen-inc-amgn/1599242.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.